Published in Women's Health Weekly, February 1st, 2001
Femara, an aromatase inhibitor, was approved for treatment of advanced breast cancer in 1997 in women whose cancer had not responded to antiestrogen drugs. Femara was shown to be more effective than tamoxifen in a randomized, double-blinded, multinational trial of more than 900 postmenopausal women, with locally advanced or metastatic breast cancer not amenable to treatment with surgery or radiation.
In the study,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.